{"nctId":"NCT02821416","briefTitle":"Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics","startDateStruct":{"date":"2016-10-11","type":"ACTUAL"},"conditions":["Asthma"],"count":46,"armGroups":[{"label":"Benralizumab","type":"EXPERIMENTAL","interventionNames":["Biological: Benralizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Benralizumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female or male aged 18 to 65 years, inclusively, at the time of enrolment.\n3. General good health\n4. Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not more than twice weekly)\n5. Positive skin-prick test to at least one common aeroallergen\n\nExclusion Criteria:\n\n1. Current lung disease other than mild allergic asthma\n2. Any history or symptoms of disease, including, but not limited to, cardiovascular, neurologic, autoimmune or haematologic\n3. Any clinically significant abnormal findings in laboratory test results in complete blood count, coagulation, chemistry panel and urinalysis at enrolment and during screening period\n4. History of anaphylaxis to any biologic therapy or vaccine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge","description":"To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.822","spread":"4.054"},{"groupId":"OG001","value":"6.468","spread":"9.560"}]}]}]},{"type":"PRIMARY","title":"Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge","description":"To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.152","spread":"8.834"},{"groupId":"OG001","value":"16.275","spread":"10.235"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Nasopharyngitis","Headache","Bronchitis","Myalgia","Dizziness"]}}}